​​

Day 1: April 13, 2026

 

Setting The Stage 9:30 –9:45 (15 min.)

 

The Layout of the Workshop: 9:45-9:50 (5 minutes)

Richard Gold, Distinguished James McGill Professor, McGill University, and Chief Policy and Partnerships Officer, Conscience

​

Session 1: Economic and other benefits of open science and innovation partnerships 9:50- 10:50 (60 min.)

Moderator: Alessandra Colecchia, Head of Science and Technology Policy Division, Directorate for Science, Technology and Innovation, OECD

​

Speakers:

• Jie Fang, Postdoctoral Researcher, McGill Centre for Intellectual Property: open collaborations in drug development

• Eric Sutherland, Senior Economist, Health Division, Directorate for Employment, Labour and Social Affairs, OECD

• BIAC?
   

This session will investigate the current state of knowledge on the economic and broader social effect of OSIPs on health-related innovation.
 

Guiding questions:

• What are the economic impact of OSIPs in general?

• What do we know about the economic impact of health-related collaborative platforms and of OSIPs in particular?

• What other benefits are being sought?

• How can governments help in providing and analysing the evidence about OSIPs on health-related innovation?

​​​

Panel discussion/Q&A

 

Coffee Break (10:50-11:20)

 

Session 2: The Scope of Open Science and Innovation Partnerships 11:20-12:50 (90 min.)
 

Moderator: TBD

Speakers:

• Marie Louise Conradsen, Head of Open Science, Aarhus University

• Max Morgan, CEO, Agora Open Science Trust

• Akshay Maheshwari, CEO, b.next

• Atsushi Ugajin, Executive Managing Director, Healthcare AI Platform Collaborative Innovation Partnership
   

This session will examine the type of activities undertaken by current OSIPs, in particular how far their joint activities extend beyond preclinical studies. Leaders of existing OSIPs will summarize the scope of their activities and the potential, if any, of moving further toward bringing a product or service to market.
 

Guiding questions:

• What types of activities are currently comprised within OSIPs?

• Does the potential exist to expand the scope of activities further down toward product markets?

• Do OSIPs focus more on products directed at patients or at the creation of intermediate tools (e.g., for data analysis)?​

​​

Panel discussion/Q&A

 

Lunch Break (12:50-14:20)

 

Session 3: Challenges and Opportunities in Creating and Managing Open Science Innovation Partnerships 14:20-15:50 (90 mins)
 

This session will consider lessons learned by founders and managers of OSIPs in relation to starting these partnerships and managing them as they grow and operate.  

​

Guiding questions:

• How do you build an OSIP and govern it?

• What is the value proposition of these partnerships for different stakeholders?

• How does a partnership build interest among stakeholders and investors?

• What were the key barriers to the creation of an OSIP and how can one overcome them?

• What challenges do OSIPs face as they mature?
   

Moderator: TBD
 

Speakers:

• Ed Griffen, Technical Director and Co-Founder at Medchemica Ltd

• Chantalle Dana Driever, Program Coordinator, ODIN

• Peter Sampson, VP Drug Discovery & Development, Agora Open Science Trust

• Anton Molina, Director of Open Source Ecosystem, b.next
   

Panel discussion/Q&A

 

Coffee Break (15:50-16:20) 

 

Session 4: How Do OSIPs Manage Intellectual Property, Regulatory Exclusivities, and Contracts Within the Partnerships and With the Public? 16:20-17:50 (90 mins)

This session explores the forms of intellectual property and regulatory exclusivities used by OSIPs, and how those partnerships manage and contract around that IP.
 

Guiding questions:

• Which forms of intellectual property and regulatory exclusivities are most useful to conducting research, sharing results, and building tools within OSIPs?

• Which forms of intellectual property and regulatory exclusivities are most useful in translating the outputs of OSIPs into innovation?

• What are the tradeoffs between intellectual property protection and open sharing in the development of innovative products and services?
   

Moderator: Richard Gold, Distinguished James McGill Professor; Director, Center for Intellectual Property Policy; Chief Policy and Partnerships Officer, Conscience
 

Speakers:

• Katharina Miller, Partner, Miller International and Adviser, IP4OS

• Pascale Boulet, Intellectual Property and Access Leader, DNDi

• Max Morgan, CEO, Agora Open Science Trust
   

Panel discussion/Q&A

 

Day 1 Concluding Remarks 17:50-18:00 (10 mins)

 

Cocktail (18:00)

​

Day 2: April 14, 2026 9:30 to 12:55

Overview of Day 1 and Plan for Day 2 9:30-9:40 (10 mins)

 

Session 5: The role and the management of data within open science innovation partnerships 9:40-11:10 (90 mins)
 

This session looks at the role that data, particularly large sets of data, play within OSIPs. Access to high-quality and large data and material sets underlies most OSIPs so the management of that data is critical.

Guiding questions:
 

• What types of data and materials are best managed through OSIPs?

• How does making data openly available balance with firm needs for exclusivity?

• How do OSIPs ensure equitable access to data and materials?

• Do open collaborative platforms create or advance health data spaces?
   

Moderator: David Castle, residence at the Office of the Chief Science Advisor, Canada  and Professor in the School of Public Administration and the Gustavson School of Business at the University of Victoria

Speakers:

• Jerome de Barros, Policy Officer Digital Health, DG SANTE, European Commission

• Karl Luyben, President of the EOSC Association and Rector Magnificus Emeritus of the Delft University of Technology

• Limor Shmerling, Senior Policy Analyst, Directorate for Science, Technology and Innovation, OECD

Panel discussion/Q&A

 

Coffee Break (11:10-11:40)

 

Session 6: The role of governments in supporting open science innovation partnerships 11:40-12:50 (70 mins)

This session will examine how governments can support OSIPs in facilitating product and service innovation. Governments play various roles, from funding open collaborative platforms, funding the members of these partnerships, to developing policy and legislation over intellectual property, regulatory exclusivities, and taxation.

Guiding questions:

• What forms of government funding are best suited to support OSIPs?

• What kind of incentives, beyond funding, can government provide to OSIPs and their members?

• How can leaders of OSIPs best contribute to government policymaking?

Moderator: David Winickoff, Senior Policy Analyst, Directorate for Science, Technology and Innovation, OECD

Speakers:

• Marc Fortin, Professor of Practice, Max Bell School of Public Policy, McGill University

• Hannah Hope, Open Research Lead, Wellcome Trust

 
Panel discussion/Q&A

 

Concluding Remarks 12:50-13:00 (10 mins)